An engineered oncolytic herpes virus (OVH) initiates TAA-specific immune responses induced by ICD, which leads to systemic tumor regression in an antigen-targeting therapeutic antibody-dependent manner.94 In situ therapeutic cancer vaccination with membrane-tethered IL-2-armed OV (vvDD-mIL2) plus a TLR 9 ligand (CpG) yielded systemic immunization.258 Moreover, OVs can also be further armed with tumor antigens to enhance the antitumor immune response. This evidence concerns the gene IL2 and neoplasm.